A Study to Evaluate the Treatment Outcome and Development of New Mutations in Patients With Imatinib- and/or Nilotinib-Failure Philadelphia Chromosome Positive (Ph+) Leukemia With Highly Nilotinib Resistant Mutations Treated With Dasatinib

Trial Profile

A Study to Evaluate the Treatment Outcome and Development of New Mutations in Patients With Imatinib- and/or Nilotinib-Failure Philadelphia Chromosome Positive (Ph+) Leukemia With Highly Nilotinib Resistant Mutations Treated With Dasatinib

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2016

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Leukaemia
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 23 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top